Sagimet Biosciences (SGMT) Projected to Post Earnings on Wednesday

Sagimet Biosciences (NASDAQ:SGMT) is expected to be posting its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect Sagimet Biosciences to post earnings of ($0.43) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 12, 2026 at 9:30 AM ET.

Sagimet Biosciences Price Performance

SGMT stock opened at $5.62 on Wednesday. The company has a fifty day moving average price of $5.81 and a 200 day moving average price of $6.71. Sagimet Biosciences has a 12 month low of $1.73 and a 12 month high of $11.41. The company has a market cap of $182.76 million, a price-to-earnings ratio of -3.16 and a beta of 3.35.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Barclays started coverage on shares of Sagimet Biosciences in a report on Tuesday, January 27th. They issued an “equal weight” rating and a $8.00 target price for the company. Zacks Research lowered Sagimet Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Citizens Jmp upped their price objective on Sagimet Biosciences from $33.00 to $35.00 and gave the company a “market outperform” rating in a research note on Friday, November 14th. Guggenheim began coverage on Sagimet Biosciences in a research report on Tuesday, February 3rd. They set a “buy” rating and a $27.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sagimet Biosciences in a research note on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $26.00.

Insider Buying and Selling

In other Sagimet Biosciences news, CEO David Happel sold 12,101 shares of the business’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $5.36, for a total transaction of $64,861.36. Following the sale, the chief executive officer directly owned 677,621 shares in the company, valued at approximately $3,632,048.56. The trade was a 1.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 14.70% of the company’s stock.

Institutional Trading of Sagimet Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in SGMT. Affinity Asset Advisors LLC boosted its holdings in Sagimet Biosciences by 228.1% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,148,245 shares of the company’s stock worth $6,798,000 after buying an additional 798,245 shares in the last quarter. Millennium Management LLC lifted its position in shares of Sagimet Biosciences by 6,484.7% during the 3rd quarter. Millennium Management LLC now owns 776,377 shares of the company’s stock valued at $5,326,000 after acquiring an additional 788,537 shares during the period. Marshall Wace LLP purchased a new stake in shares of Sagimet Biosciences during the 4th quarter worth approximately $4,620,000. Schonfeld Strategic Advisors LLC boosted its stake in shares of Sagimet Biosciences by 462.4% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 523,774 shares of the company’s stock worth $3,593,000 after acquiring an additional 430,644 shares in the last quarter. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of Sagimet Biosciences in the 4th quarter worth approximately $1,802,000. Institutional investors and hedge funds own 87.86% of the company’s stock.

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.